from those associated with the use of other oral contraceptives.
The EURAS study monitored 58 674 oral contraceptive users⎯of whom 16 534 women had used Yasmin⎯at 1113 study centers in 7 European countries. 3 The INGENIX study followed the health histories of 22 429 women who used Yasmin and 44 858 women who had initiated use of other oral contraceptives using insurance-based claims data from one of the largest US health care insurer. 4 Overall, these studies represent more than 180 000 women-years of observation, including 42 702 women-years of Yasmin use. In the EURAS study, Cox regression analysis of cardiovascular outcomes yielded hazard ratios for Yasmin compared with levonorgestrelcontaining oral contraceptives and other oral contraceptives of 1.0 and 0.8 (upper 95% confidence limits, 1.8 and 1.3, respectively) for venous thromboembolism and 0.3 and 0.3 (upper 95% confidence limits, 1.2 and 1.5, respectively) for arterial thromboembolism. 3 Similarly, in the INGENIX study, the rate of venous thromboembolism did not differ between the 2 groups (relative risk, 0.9; 95% confidence interval, 0.5-1.6). 4 We emphasize that these data should not be misconstrued as evidence of a superior safety profile for Yasmin as suggested by Orti et al. All safety data on Yasmin to date, including the data from the large epidemiological studies as well as spontaneous adverse event reports, have been shared with the respective regulatory authorities and are published. Based on the extensive safety data available, the European Health Authorities assessed that "there is no indication that users of Yasmin would be at higher risk of VTE than users of other COCs [combined oral contraceptives]." This information was integrated into the Yasmin label in November 2004.
We encourage healthcare professionals to review the extensive safety data available on Yasmin.
To the Editor:
In a letter to the editor, Ortí et al 1 reported a single case of myocardial infarction in a 39-year-old heavy smoker who had used Yasmin (drospirenone 3 mg and ethinyl estradiol 30 μg) for 2 years. Cardiovascular disease is rare in premenopausal women and, as stated by the authors, the association between myocardial infarction and combined oral contraceptives use is controversial. 2 We would like to address 2 points stated about Yasmin-regarding its thrombosis risk and the data supporting its safety profile-that we believe are misstatements and warrant further clarification. Contrary to Dr Orti's statement that "it has been suggested that it [Yasmin] has a lower risk of thrombosis than other oral contraceptives," we wish to point out that Bayer Schering Pharma AG does not and has never suggested that Yasmin is safer than other combined oral contraceptives. As market leaders in contraception, Bayer Schering Pharma AG has supported extensive postmarketing studies comparing the safety of Yasmin with other combined oral contraceptives. Currently, data on Yasmin safety has been gathered in more than 23 million women-years of use. These data include information from clinical development trials, large prospective postmarketing active surveillance cohort studies, and spontaneous adverse event reporting.
Two very large, independently conducted, prospective, comparative, cohort studies have been conducted that compared safety data from women using Yasmin with users of other oral contraceptives, with a special emphasis on cardiovascular outcomes such as venous and arterial thromboembolic events. 3, 4 Both studies, the European Active Surveillance (EURAS) study and the INGENIX study, were conducted for Yasmin as postapproval regulatory commitments to European and US Health Authorities. Both these studies confirmed that the risk of adverse cardiovascular outcomes for Yasmin does not differ
